33,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
17 °P sammeln
  • Broschiertes Buch

Cancer is the second leading cause of death in the world. The available treatments have a number of limitations, such as side effects and low efficiency. In the search for new treatments, mitochondria have been highlighted as a promising target for cancer treatment due to the existence of an important relationship between mitochondrial dysfunction and tumourigenesis. Thus, an increase in the number of studies has been observed in recent years, with interest in compounds with action on mitochondrial targets ('mitocans') as an alternative for the treatment of cancer. The aim of this narrative…mehr

Produktbeschreibung
Cancer is the second leading cause of death in the world. The available treatments have a number of limitations, such as side effects and low efficiency. In the search for new treatments, mitochondria have been highlighted as a promising target for cancer treatment due to the existence of an important relationship between mitochondrial dysfunction and tumourigenesis. Thus, an increase in the number of studies has been observed in recent years, with interest in compounds with action on mitochondrial targets ('mitocans') as an alternative for the treatment of cancer. The aim of this narrative review was to describe the advances in cancer therapy with the emergence of mitochondrial drugs.
Autorenporträt
Karen Lima has a bachelor's degree in Pharmacy from the Federal Rural University of Rio de Janeiro (2017). She was a scientific initiation student in the Chemistry Department (2012-2016) and a tutor in Pharmacovigilance and Pharmaceutical Care (2017).